Abbas Kazimi joined Nimbus in 2014 and was appointed CEO in 2025. Previously, he served as Chief Business Officer since 2020, following his leadership in corporate and business development. He has driven key corporate initiatives that have enabled Nimbus to raise over $600 million in equity financing and secure transactions with pharmaceutical partners totaling over $7 billion in upfront and milestone capital. In addition to corporate strategy and business operations, Abbas has led the expansion of Nimbus’ computational drug discovery engine, forging strategic alliances with innovators in experimental approaches that complement Nimbus’ deep expertise in structure-based drug discovery and medicinal chemistry. With over 15 years of experience in life sciences transactions, Abbas has worked extensively with industry partners and financial investors. Before joining Nimbus, he was with Extera Partners, LLC (formerly PureTech Development, LLC), where he provided strategic advisory, supported fundraising efforts, and executed numerous business development transactions. Prior to that, he was with JSB-Partners, LP, a specialized investment banking and advisory firm serving biotechnology and pharmaceutical companies. Abbas currently serves on the board of Unnatural Products (UNP), a biotech developing orally delivered macrocyclic peptides to address previously undruggable targets. He earned his BA from the University of Texas at Austin and his MS from Harvard University.